Filtered By:
Procedure: Transplants
Therapy: Immunotherapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1525 results found since Jan 2013.

Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: A case report and review of literature
CONCLUSION: Organ transplant recipients with complete response to immunotherapy for cutaneous squamous cell carcinoma may continue to respond despite early treatment cessation. This may reduce the risks of late immune-related adverse events and acute graft rejection.PMID:37734447 | DOI:10.1016/j.trim.2023.101932
Source: Transplant Immunology - September 21, 2023 Category: Transplant Surgery Authors: Ziyao Lu Mohammed Afzal Keisuke Shirai Source Type: research

Human CD34 < sup > + < /sup > -derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8 < sup > + < /sup > T cell and NK cell responses in vitro and in vivo
In this study, we aimed to dissect the phenotypic identity of these non-DCs and their potential immune modulatory functions on the potency of cDCs and pDCs in stimulating tumor-reactive CD8+ T and NK cell responses, in order to obtain rationale for clinical translation of our DC-complete vaccine. The non-DC compartment was heterogeneous and comprised of myeloid progenitors and (immature) granulocyte- and monocyte-like cells. Importantly, non-DCs potentiated toll-like receptor-induced DC maturation, as reflected by increased expression of co-stimulatory molecules and enhanced cDC-derived IL-12 and pDC-derived IFN-α product...
Source: Cellular and Molecular Life Sciences : CMLS - September 20, 2023 Category: Cytology Authors: Jesper van Eck van der Sluijs Diede van Ens Jolanda Brummelman Daan Heister Aastha Sareen Lisa Truijen Dorette S van Ingen Schenau Mirjam H M Heemskerk Marieke Griffioen Michel G D Kester Nicolaas P M Schaap Joop H Jansen Anniek B van der Waart Harry Dols Source Type: research

Intratumoral Bacteria as Mediators of Cancer Immunotherapy Response
Cancer Res. 2023 Sep 15;83(18):2985-2986. doi: 10.1158/0008-5472.CAN-23-1857.ABSTRACTMultiple lines of evidence spanning from animal models to human clinical trials indicate that the microbiome influences cancer immunotherapy response. Whereas initial studies focused exclusively on the gastrointestinal (gut) microbiota-tumor axis, more recent studies have examined the possibility that bacteria located within tumor cells or within the tumor microenvironment mediate cancer treatment response. Strikingly, this phenomenon has been demonstrated in cancers that arise in anatomic locations that are traditionally thought to be dev...
Source: Cell Research - September 15, 2023 Category: Cytology Authors: Karen S Sfanos Source Type: research

Accelerated Chronic Lymphocytic Leukemia and Richter Transformation in the Era of Novel Agents
Acta Haematol. 2023 Sep 4. doi: 10.1159/000533664. Online ahead of print.ABSTRACTBACKGROUND: Tremendous developments in the field of Chronic Lymphocytic leukemia (CLL) in recent years has led to a revolutionary change in the treatment approach, which today is based on targeted treatments with a good response and optimal prognosis. Nevertheless, CLL can present or progress to "accelerated CLL" (A-CLL) or to "Richter transformation" (RT) and these two entities have a more aggressive course and are still characterized by challenges in the fields of diagnosis, and therapy. In the current review we summarized the latest knowled...
Source: Acta Haematologica - September 4, 2023 Category: Hematology Authors: Ilana Levy Yurkovski Tamar Tadmor Source Type: research

Two-pronged immunotherapy approach could treat most blood cancers
The genetically modified immune cells known as CAR-T cells have cured thousands of people with blood cancers, but so far the treatments only work against a few types of the disease. Today in Science Translational Medicine ( STM ), a research team describes a provocative CAR-T strategy to tackle most blood cancers. Working in mice, the scientists sicced the immune cells on a protein common to nearly all cancerous blood cells. Because that protein is also found on normal blood-forming stem cells, the team also replaced those vital cells with ones genetically tweaked to be invisible to the cancer fighters, p...
Source: Science of Aging Knowledge Environment - August 31, 2023 Category: Geriatrics Source Type: research

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study
We report the final 5-year analysis. Eighty patients (≥18 years, 1-3 prior systemic therapies, ECOG PS 0-2) received co-administered tafasitamab and lenalidomide for up to 12 cycles, followed by tafasitamab monotherapy until disease progression (PD) or unacceptable toxicity. Primary endpoint was best objective response rate (ORR). Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Exploratory analyses evaluated efficacy endpoints by prior lines of therapy (pLoT). At data cut-off on November 14, 2022, ORR was 57.5%, with complete response (CR) of 41...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Johannes Duell Pau Abrisqueta Marc Andre Gianluca Gaidano Eva Gonzales-Barca Wojciech Jurczak Nagesh Kalakonda Anna Marina Liberati Kami J Maddocks Tobias Menne Zsolt Nagy Olivier Tournilhac Christian Kuffer Abhishek Bakuli Aasim Amin Konstantin Gurbanov Source Type: research

Engineered hematopoietic and immune cells derived from human pluripotent stem cells
Exp Hematol. 2023 Aug 21:S0301-472X(23)01674-0. doi: 10.1016/j.exphem.2023.08.006. Online ahead of print.ABSTRACTFor the past decade, significant advances have been achieved in human hematopoietic stem cell (HSC) transplantation for treating various blood diseases and cancers. However, challenges remain with the quality control, amount, and cost of HSCs and HSC-derived immune cells. The advent of human pluripotent stem cells (hPSCs) may transform HSC transplantation and cancer immunotherapy by providing a cost-effective and scalable cell source for fundamental studies and translational applications. In this review, we disc...
Source: Cancer Control - August 23, 2023 Category: Cancer & Oncology Authors: Yun Chang Sydney N Hummel Juhyung Jung Gyuhyung Jin Qing Deng Xiaoping Bao Source Type: research

PML/RARa leukemia induced murine model for immunotherapy evaluation
Transpl Immunol. 2023 Aug 18:101919. doi: 10.1016/j.trim.2023.101919. Online ahead of print.ABSTRACTEven though leukemia murine models are valuable tools for new drug therapy studies, most of these models consist of immunocompromised mice, which do not exhibit immune responses. In order to obtain an adequate leukemia model, we established an acute promyelocytic leukemia transplantation-based model (PML/RARa) in immunocompetent BALB/c mice, thus making it possible to study drug-induced cellular immune responses in leukemia. The development of PML/RARa leukemia was confirmed by leukocytosis (76.27 ± 21.8 vs. 3.40 ± 1.06; P...
Source: Transplant Immunology - August 20, 2023 Category: Transplant Surgery Authors: Rodrigo N Shiraishi Andr é L Bombeiro Tamara C L Castro Fernanda I Della Via Irene Santos Eduardo M Rego Sara T O Saad Cristiane O Torello Source Type: research